

# Nuclear RNA Networks, Inc.

Pancreatic Ductal  
Adenocarcinoma (PDAC)


## The Problem We Are Currently Addressing

Cancers with KRAS-mutations are highly  
refractory to conventional treatment

- KRAS mutations ~ 25% of all human cancers
- To date: no FDA-approved therapies targeting the KRAS G12D mutation  
= 34% Pancreatic cancers, 13% Colorectal

## Why?

## Acquired Resistance



PDAC: projected to be  
**2<sup>nd</sup> leading cause of cancer  
deaths in the US by 2030**

Siegel RL, Miller KD, Fuchs HE, Jemal A. **Cancer statistics, 2022.** CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. PMID: 35020204.  
Norton C, Shaw MS, Rubnitz Z, et al. KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA Netw Open. 2025;8(1):e2453588. doi:10.1001/jamanetworkopen.2024.53588

NucRNA NON-CONFIDENTIAL

11/24/25